Your browser doesn't support javascript.
loading
Phenotypic screening reveals TNFR2 as a promising target for cancer immunotherapy.
Williams, Geoffrey S; Mistry, Bina; Guillard, Sandrine; Ulrichsen, Jane Coates; Sandercock, Alan M; Wang, Jun; González-Muñoz, Andrea; Parmentier, Julie; Black, Chelsea; Soden, Jo; Freeth, Jim; Jovanovic, Jelena; Leyland, Rebecca; Al-Lamki, Rafia S; Leishman, Andrew J; Rust, Steven J; Stewart, Ross; Jermutus, Lutz; Bradley, John R; Bedian, Vahe; Valge-Archer, Viia; Minter, Ralph; Wilkinson, Robert W.
Afiliación
  • Williams GS; MedImmune Ltd., Granta Park, Cambridge, CB21 6GH, UK.
  • Mistry B; MedImmune Ltd., Granta Park, Cambridge, CB21 6GH, UK.
  • Guillard S; MedImmune Ltd., Granta Park, Cambridge, CB21 6GH, UK.
  • Ulrichsen JC; MedImmune Ltd., Granta Park, Cambridge, CB21 6GH, UK.
  • Sandercock AM; MedImmune Ltd., Granta Park, Cambridge, CB21 6GH, UK.
  • Wang J; Department of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge, CB2 0QQ, UK.
  • González-Muñoz A; MedImmune Ltd., Granta Park, Cambridge, CB21 6GH, UK.
  • Parmentier J; Oncology iMED, AstraZeneca-R&D Boston, Waltham, MA 02451, USA.
  • Black C; MedImmune LLC, Gaithersburg, MD 20878, USA.
  • Soden J; Retrogenix Ltd, Whaley Bridge, High Peak, SK23 7LY, UK.
  • Freeth J; Retrogenix Ltd, Whaley Bridge, High Peak, SK23 7LY, UK.
  • Jovanovic J; MedImmune Ltd., Granta Park, Cambridge, CB21 6GH, UK.
  • Leyland R; MedImmune Ltd., Granta Park, Cambridge, CB21 6GH, UK.
  • Al-Lamki RS; Department of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge, CB2 0QQ, UK.
  • Leishman AJ; MedImmune Ltd., Granta Park, Cambridge, CB21 6GH, UK.
  • Rust SJ; MedImmune Ltd., Granta Park, Cambridge, CB21 6GH, UK.
  • Stewart R; MedImmune Ltd., Granta Park, Cambridge, CB21 6GH, UK.
  • Jermutus L; MedImmune Ltd., Granta Park, Cambridge, CB21 6GH, UK.
  • Bradley JR; Department of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge, CB2 0QQ, UK.
  • Bedian V; Oncology iMED, AstraZeneca-R&D Boston, Waltham, MA 02451, USA.
  • Valge-Archer V; MedImmune Ltd., Granta Park, Cambridge, CB21 6GH, UK.
  • Minter R; MedImmune Ltd., Granta Park, Cambridge, CB21 6GH, UK.
  • Wilkinson RW; MedImmune Ltd., Granta Park, Cambridge, CB21 6GH, UK.
Oncotarget ; 7(42): 68278-68291, 2016 10 18.
Article en En | MEDLINE | ID: mdl-27626702
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Linfocitos T Reguladores / Receptores Tipo II del Factor de Necrosis Tumoral / Inmunoterapia / Neoplasias Tipo de estudio: Diagnostic_studies / Screening_studies Límite: Animals / Female / Humans Idioma: En Año: 2016 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Linfocitos T Reguladores / Receptores Tipo II del Factor de Necrosis Tumoral / Inmunoterapia / Neoplasias Tipo de estudio: Diagnostic_studies / Screening_studies Límite: Animals / Female / Humans Idioma: En Año: 2016 Tipo del documento: Article